Review




Structured Review

Broad Institute Inc rnai consortium (trc) shrna library
Immunoblotting of PAI-1 protein in HCT116 MD and HD knocked down for the protein using two unique shRNAs ( A ). Fold change of PAI-1 protein in cell culture supernatant of HCT116 MD and HD knocked down for the protein relative to MD <t>shRNA</t> control (shCtrl) ( B ). Fold change of dose response to 48 hrs oxaliplatin treatment in HCT116 MD and HD knocked down for the protein relative to MD shCtrl ( C ). Representative dose response curves of HCT116-MD shCtrl, PAI-1 sh3 and sh5 ( D ) and HCT116-HD shCtrl, PAI-1 sh3 and sh5 ( E ) to 48 hrs of oxaliplatin treatment. F-F’, Inhibition of metastasis in oxaliplatin treated HCT116 model using tiplaxtinin. Three representative H&E staining and corresponding quantifications ( F and F’ ) of lung sections from mice harboring HCT116 PAR xenografts treated with oxaliplatin, alone or in combination with tiplaxtinin, until spontaneous metastasis (refer to section ‘Impact of concomitant administration of tiplaxtinin and oxaliplatin on metastasis’ under Materials and Methods). For quantification number of nodule positive area was normalized to total lung area (n= at least 8). Statistical significance was determined using Ordinary one-way ANOVA followed by Sidak’s multiple comparisons test for Fig. B, C, and using two-tailed unpaired t-test for Fig. F’. A p-value of <0.05 was considered significant for all analyses, unless stated otherwise.
Rnai Consortium (Trc) Shrna Library, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rnai consortium (trc) shrna library/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
rnai consortium (trc) shrna library - by Bioz Stars, 2026-06
90/100 stars

Images

1) Product Images from "Modelling oxaliplatin resistance in colorectal cancer reveals a SERPINE1 -based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype"

Article Title: Modelling oxaliplatin resistance in colorectal cancer reveals a SERPINE1 -based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype

Journal: bioRxiv

doi: 10.1101/2024.12.17.628817

Immunoblotting of PAI-1 protein in HCT116 MD and HD knocked down for the protein using two unique shRNAs ( A ). Fold change of PAI-1 protein in cell culture supernatant of HCT116 MD and HD knocked down for the protein relative to MD shRNA control (shCtrl) ( B ). Fold change of dose response to 48 hrs oxaliplatin treatment in HCT116 MD and HD knocked down for the protein relative to MD shCtrl ( C ). Representative dose response curves of HCT116-MD shCtrl, PAI-1 sh3 and sh5 ( D ) and HCT116-HD shCtrl, PAI-1 sh3 and sh5 ( E ) to 48 hrs of oxaliplatin treatment. F-F’, Inhibition of metastasis in oxaliplatin treated HCT116 model using tiplaxtinin. Three representative H&E staining and corresponding quantifications ( F and F’ ) of lung sections from mice harboring HCT116 PAR xenografts treated with oxaliplatin, alone or in combination with tiplaxtinin, until spontaneous metastasis (refer to section ‘Impact of concomitant administration of tiplaxtinin and oxaliplatin on metastasis’ under Materials and Methods). For quantification number of nodule positive area was normalized to total lung area (n= at least 8). Statistical significance was determined using Ordinary one-way ANOVA followed by Sidak’s multiple comparisons test for Fig. B, C, and using two-tailed unpaired t-test for Fig. F’. A p-value of <0.05 was considered significant for all analyses, unless stated otherwise.
Figure Legend Snippet: Immunoblotting of PAI-1 protein in HCT116 MD and HD knocked down for the protein using two unique shRNAs ( A ). Fold change of PAI-1 protein in cell culture supernatant of HCT116 MD and HD knocked down for the protein relative to MD shRNA control (shCtrl) ( B ). Fold change of dose response to 48 hrs oxaliplatin treatment in HCT116 MD and HD knocked down for the protein relative to MD shCtrl ( C ). Representative dose response curves of HCT116-MD shCtrl, PAI-1 sh3 and sh5 ( D ) and HCT116-HD shCtrl, PAI-1 sh3 and sh5 ( E ) to 48 hrs of oxaliplatin treatment. F-F’, Inhibition of metastasis in oxaliplatin treated HCT116 model using tiplaxtinin. Three representative H&E staining and corresponding quantifications ( F and F’ ) of lung sections from mice harboring HCT116 PAR xenografts treated with oxaliplatin, alone or in combination with tiplaxtinin, until spontaneous metastasis (refer to section ‘Impact of concomitant administration of tiplaxtinin and oxaliplatin on metastasis’ under Materials and Methods). For quantification number of nodule positive area was normalized to total lung area (n= at least 8). Statistical significance was determined using Ordinary one-way ANOVA followed by Sidak’s multiple comparisons test for Fig. B, C, and using two-tailed unpaired t-test for Fig. F’. A p-value of <0.05 was considered significant for all analyses, unless stated otherwise.

Techniques Used: Western Blot, Cell Culture, shRNA, Control, Inhibition, Staining, Two Tailed Test



Similar Products

96
Broad Clinical Labs rnai consortium shrna library
Rnai Consortium Shrna Library, supplied by Broad Clinical Labs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rnai consortium shrna library/product/Broad Clinical Labs
Average 96 stars, based on 1 article reviews
rnai consortium shrna library - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

90
Broad Institute Inc rnai consortium (trc) shrna library
Immunoblotting of PAI-1 protein in HCT116 MD and HD knocked down for the protein using two unique shRNAs ( A ). Fold change of PAI-1 protein in cell culture supernatant of HCT116 MD and HD knocked down for the protein relative to MD <t>shRNA</t> control (shCtrl) ( B ). Fold change of dose response to 48 hrs oxaliplatin treatment in HCT116 MD and HD knocked down for the protein relative to MD shCtrl ( C ). Representative dose response curves of HCT116-MD shCtrl, PAI-1 sh3 and sh5 ( D ) and HCT116-HD shCtrl, PAI-1 sh3 and sh5 ( E ) to 48 hrs of oxaliplatin treatment. F-F’, Inhibition of metastasis in oxaliplatin treated HCT116 model using tiplaxtinin. Three representative H&E staining and corresponding quantifications ( F and F’ ) of lung sections from mice harboring HCT116 PAR xenografts treated with oxaliplatin, alone or in combination with tiplaxtinin, until spontaneous metastasis (refer to section ‘Impact of concomitant administration of tiplaxtinin and oxaliplatin on metastasis’ under Materials and Methods). For quantification number of nodule positive area was normalized to total lung area (n= at least 8). Statistical significance was determined using Ordinary one-way ANOVA followed by Sidak’s multiple comparisons test for Fig. B, C, and using two-tailed unpaired t-test for Fig. F’. A p-value of <0.05 was considered significant for all analyses, unless stated otherwise.
Rnai Consortium (Trc) Shrna Library, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rnai consortium (trc) shrna library/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
rnai consortium (trc) shrna library - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Broad Institute Inc trc library database of the rnai consortium shrna library
Immunoblotting of PAI-1 protein in HCT116 MD and HD knocked down for the protein using two unique shRNAs ( A ). Fold change of PAI-1 protein in cell culture supernatant of HCT116 MD and HD knocked down for the protein relative to MD <t>shRNA</t> control (shCtrl) ( B ). Fold change of dose response to 48 hrs oxaliplatin treatment in HCT116 MD and HD knocked down for the protein relative to MD shCtrl ( C ). Representative dose response curves of HCT116-MD shCtrl, PAI-1 sh3 and sh5 ( D ) and HCT116-HD shCtrl, PAI-1 sh3 and sh5 ( E ) to 48 hrs of oxaliplatin treatment. F-F’, Inhibition of metastasis in oxaliplatin treated HCT116 model using tiplaxtinin. Three representative H&E staining and corresponding quantifications ( F and F’ ) of lung sections from mice harboring HCT116 PAR xenografts treated with oxaliplatin, alone or in combination with tiplaxtinin, until spontaneous metastasis (refer to section ‘Impact of concomitant administration of tiplaxtinin and oxaliplatin on metastasis’ under Materials and Methods). For quantification number of nodule positive area was normalized to total lung area (n= at least 8). Statistical significance was determined using Ordinary one-way ANOVA followed by Sidak’s multiple comparisons test for Fig. B, C, and using two-tailed unpaired t-test for Fig. F’. A p-value of <0.05 was considered significant for all analyses, unless stated otherwise.
Trc Library Database Of The Rnai Consortium Shrna Library, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/trc library database of the rnai consortium shrna library/product/Broad Institute Inc
Average 90 stars, based on 1 article reviews
trc library database of the rnai consortium shrna library - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Fisher Scientific shrnas specific for rat genes from trc (the rnai consortium) library in plko lentiviral vectors
Immunoblotting of PAI-1 protein in HCT116 MD and HD knocked down for the protein using two unique shRNAs ( A ). Fold change of PAI-1 protein in cell culture supernatant of HCT116 MD and HD knocked down for the protein relative to MD <t>shRNA</t> control (shCtrl) ( B ). Fold change of dose response to 48 hrs oxaliplatin treatment in HCT116 MD and HD knocked down for the protein relative to MD shCtrl ( C ). Representative dose response curves of HCT116-MD shCtrl, PAI-1 sh3 and sh5 ( D ) and HCT116-HD shCtrl, PAI-1 sh3 and sh5 ( E ) to 48 hrs of oxaliplatin treatment. F-F’, Inhibition of metastasis in oxaliplatin treated HCT116 model using tiplaxtinin. Three representative H&E staining and corresponding quantifications ( F and F’ ) of lung sections from mice harboring HCT116 PAR xenografts treated with oxaliplatin, alone or in combination with tiplaxtinin, until spontaneous metastasis (refer to section ‘Impact of concomitant administration of tiplaxtinin and oxaliplatin on metastasis’ under Materials and Methods). For quantification number of nodule positive area was normalized to total lung area (n= at least 8). Statistical significance was determined using Ordinary one-way ANOVA followed by Sidak’s multiple comparisons test for Fig. B, C, and using two-tailed unpaired t-test for Fig. F’. A p-value of <0.05 was considered significant for all analyses, unless stated otherwise.
Shrnas Specific For Rat Genes From Trc (The Rnai Consortium) Library In Plko Lentiviral Vectors, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/shrnas specific for rat genes from trc (the rnai consortium) library in plko lentiviral vectors/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
shrnas specific for rat genes from trc (the rnai consortium) library in plko lentiviral vectors - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

96
Addgene inc rnai consortium shrna library
Immunoblotting of PAI-1 protein in HCT116 MD and HD knocked down for the protein using two unique shRNAs ( A ). Fold change of PAI-1 protein in cell culture supernatant of HCT116 MD and HD knocked down for the protein relative to MD <t>shRNA</t> control (shCtrl) ( B ). Fold change of dose response to 48 hrs oxaliplatin treatment in HCT116 MD and HD knocked down for the protein relative to MD shCtrl ( C ). Representative dose response curves of HCT116-MD shCtrl, PAI-1 sh3 and sh5 ( D ) and HCT116-HD shCtrl, PAI-1 sh3 and sh5 ( E ) to 48 hrs of oxaliplatin treatment. F-F’, Inhibition of metastasis in oxaliplatin treated HCT116 model using tiplaxtinin. Three representative H&E staining and corresponding quantifications ( F and F’ ) of lung sections from mice harboring HCT116 PAR xenografts treated with oxaliplatin, alone or in combination with tiplaxtinin, until spontaneous metastasis (refer to section ‘Impact of concomitant administration of tiplaxtinin and oxaliplatin on metastasis’ under Materials and Methods). For quantification number of nodule positive area was normalized to total lung area (n= at least 8). Statistical significance was determined using Ordinary one-way ANOVA followed by Sidak’s multiple comparisons test for Fig. B, C, and using two-tailed unpaired t-test for Fig. F’. A p-value of <0.05 was considered significant for all analyses, unless stated otherwise.
Rnai Consortium Shrna Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rnai consortium shrna library/product/Addgene inc
Average 96 stars, based on 1 article reviews
rnai consortium shrna library - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

90
Thermo Fisher rnai consortium lentiviral shrna library
A. Efficient SHP-1 gene silencing in primary murine IL-2-activated NK cells. Purified C57BL/6NCrl IL-2 activated NK cells were transduced on two consecutive days with <t>TRC</t> <t>lentiviral</t> vectors and incubated for 3 days post-transduction. Transduced cells were puromycin selected for 48 hours followed by 3 days incubation. Cells were assayed for SHP-1 expression by intracellular staining with primary rabbit anti-SHP-1 and secondary anti-rabbit Alexa Fluor 488 antibodies in flow cytometry (Black). Secondary antibodies alone (Grey) was used as negative control. Data is representative of 3 experiments. B. IL-2 activated NK cells were transduced on two consecutive days with mock, shEGFP and SHP-1 <t>shRNA</t> and incubated for 3 more days. Transduced cells were puromycin-selected and used as effectors against Yac-1, P815 and RMA-S targets at E:T ratio 1∶1 in CD107a cytotoxicity assay. Background degranulation responses of the NK effectors (in the absence of target cells) were subtracted from the degranulation responses observed in the presence of the target cells. Data of three independent experiments were pooled together for statistical analyses. N.S., (p>0.05), non significant.
Rnai Consortium Lentiviral Shrna Library, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rnai consortium lentiviral shrna library/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
rnai consortium lentiviral shrna library - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

96
Broad Clinical Labs rnai consortium trc shrna library
A. Efficient SHP-1 gene silencing in primary murine IL-2-activated NK cells. Purified C57BL/6NCrl IL-2 activated NK cells were transduced on two consecutive days with <t>TRC</t> <t>lentiviral</t> vectors and incubated for 3 days post-transduction. Transduced cells were puromycin selected for 48 hours followed by 3 days incubation. Cells were assayed for SHP-1 expression by intracellular staining with primary rabbit anti-SHP-1 and secondary anti-rabbit Alexa Fluor 488 antibodies in flow cytometry (Black). Secondary antibodies alone (Grey) was used as negative control. Data is representative of 3 experiments. B. IL-2 activated NK cells were transduced on two consecutive days with mock, shEGFP and SHP-1 <t>shRNA</t> and incubated for 3 more days. Transduced cells were puromycin-selected and used as effectors against Yac-1, P815 and RMA-S targets at E:T ratio 1∶1 in CD107a cytotoxicity assay. Background degranulation responses of the NK effectors (in the absence of target cells) were subtracted from the degranulation responses observed in the presence of the target cells. Data of three independent experiments were pooled together for statistical analyses. N.S., (p>0.05), non significant.
Rnai Consortium Trc Shrna Library, supplied by Broad Clinical Labs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rnai consortium trc shrna library/product/Broad Clinical Labs
Average 96 stars, based on 1 article reviews
rnai consortium trc shrna library - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

Image Search Results


Immunoblotting of PAI-1 protein in HCT116 MD and HD knocked down for the protein using two unique shRNAs ( A ). Fold change of PAI-1 protein in cell culture supernatant of HCT116 MD and HD knocked down for the protein relative to MD shRNA control (shCtrl) ( B ). Fold change of dose response to 48 hrs oxaliplatin treatment in HCT116 MD and HD knocked down for the protein relative to MD shCtrl ( C ). Representative dose response curves of HCT116-MD shCtrl, PAI-1 sh3 and sh5 ( D ) and HCT116-HD shCtrl, PAI-1 sh3 and sh5 ( E ) to 48 hrs of oxaliplatin treatment. F-F’, Inhibition of metastasis in oxaliplatin treated HCT116 model using tiplaxtinin. Three representative H&E staining and corresponding quantifications ( F and F’ ) of lung sections from mice harboring HCT116 PAR xenografts treated with oxaliplatin, alone or in combination with tiplaxtinin, until spontaneous metastasis (refer to section ‘Impact of concomitant administration of tiplaxtinin and oxaliplatin on metastasis’ under Materials and Methods). For quantification number of nodule positive area was normalized to total lung area (n= at least 8). Statistical significance was determined using Ordinary one-way ANOVA followed by Sidak’s multiple comparisons test for Fig. B, C, and using two-tailed unpaired t-test for Fig. F’. A p-value of <0.05 was considered significant for all analyses, unless stated otherwise.

Journal: bioRxiv

Article Title: Modelling oxaliplatin resistance in colorectal cancer reveals a SERPINE1 -based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype

doi: 10.1101/2024.12.17.628817

Figure Lengend Snippet: Immunoblotting of PAI-1 protein in HCT116 MD and HD knocked down for the protein using two unique shRNAs ( A ). Fold change of PAI-1 protein in cell culture supernatant of HCT116 MD and HD knocked down for the protein relative to MD shRNA control (shCtrl) ( B ). Fold change of dose response to 48 hrs oxaliplatin treatment in HCT116 MD and HD knocked down for the protein relative to MD shCtrl ( C ). Representative dose response curves of HCT116-MD shCtrl, PAI-1 sh3 and sh5 ( D ) and HCT116-HD shCtrl, PAI-1 sh3 and sh5 ( E ) to 48 hrs of oxaliplatin treatment. F-F’, Inhibition of metastasis in oxaliplatin treated HCT116 model using tiplaxtinin. Three representative H&E staining and corresponding quantifications ( F and F’ ) of lung sections from mice harboring HCT116 PAR xenografts treated with oxaliplatin, alone or in combination with tiplaxtinin, until spontaneous metastasis (refer to section ‘Impact of concomitant administration of tiplaxtinin and oxaliplatin on metastasis’ under Materials and Methods). For quantification number of nodule positive area was normalized to total lung area (n= at least 8). Statistical significance was determined using Ordinary one-way ANOVA followed by Sidak’s multiple comparisons test for Fig. B, C, and using two-tailed unpaired t-test for Fig. F’. A p-value of <0.05 was considered significant for all analyses, unless stated otherwise.

Article Snippet: To generate stable knockdown lines, suitable bacteria clones from the RNAi Consortium (TRC) shRNA Library (Broad Institute) were selected and sub-cultured in terrific Broth (CUS-4051-1L, Axil Scientific) supplemented with 1X carbenicillin (10177012, ThermoFisher).

Techniques: Western Blot, Cell Culture, shRNA, Control, Inhibition, Staining, Two Tailed Test

A. Efficient SHP-1 gene silencing in primary murine IL-2-activated NK cells. Purified C57BL/6NCrl IL-2 activated NK cells were transduced on two consecutive days with TRC lentiviral vectors and incubated for 3 days post-transduction. Transduced cells were puromycin selected for 48 hours followed by 3 days incubation. Cells were assayed for SHP-1 expression by intracellular staining with primary rabbit anti-SHP-1 and secondary anti-rabbit Alexa Fluor 488 antibodies in flow cytometry (Black). Secondary antibodies alone (Grey) was used as negative control. Data is representative of 3 experiments. B. IL-2 activated NK cells were transduced on two consecutive days with mock, shEGFP and SHP-1 shRNA and incubated for 3 more days. Transduced cells were puromycin-selected and used as effectors against Yac-1, P815 and RMA-S targets at E:T ratio 1∶1 in CD107a cytotoxicity assay. Background degranulation responses of the NK effectors (in the absence of target cells) were subtracted from the degranulation responses observed in the presence of the target cells. Data of three independent experiments were pooled together for statistical analyses. N.S., (p>0.05), non significant.

Journal: PLoS ONE

Article Title: SHP-1 Phosphatase Is a Critical Regulator in Preventing Natural Killer Cell Self-Killing

doi: 10.1371/journal.pone.0044244

Figure Lengend Snippet: A. Efficient SHP-1 gene silencing in primary murine IL-2-activated NK cells. Purified C57BL/6NCrl IL-2 activated NK cells were transduced on two consecutive days with TRC lentiviral vectors and incubated for 3 days post-transduction. Transduced cells were puromycin selected for 48 hours followed by 3 days incubation. Cells were assayed for SHP-1 expression by intracellular staining with primary rabbit anti-SHP-1 and secondary anti-rabbit Alexa Fluor 488 antibodies in flow cytometry (Black). Secondary antibodies alone (Grey) was used as negative control. Data is representative of 3 experiments. B. IL-2 activated NK cells were transduced on two consecutive days with mock, shEGFP and SHP-1 shRNA and incubated for 3 more days. Transduced cells were puromycin-selected and used as effectors against Yac-1, P815 and RMA-S targets at E:T ratio 1∶1 in CD107a cytotoxicity assay. Background degranulation responses of the NK effectors (in the absence of target cells) were subtracted from the degranulation responses observed in the presence of the target cells. Data of three independent experiments were pooled together for statistical analyses. N.S., (p>0.05), non significant.

Article Snippet: We searched the RNAi Consortium (TRC) lentiviral shRNA library (Open Biosystems, Thermo Fisher Scientific) for potential shRNA sequences targeting against the mouse SHP-1 gene (TRCN0000028964 - 68).

Techniques: Purification, Incubation, Transduction, Expressing, Staining, Flow Cytometry, Negative Control, shRNA, Cytotoxicity Assay